^
Association details:
| Biomarker: | FGFR mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | CPL304110 (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
46O - Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies
Published date:
03/02/2023
Excerpt:
The above early study observations suggest that CPL304110 administration is associated with acceptable toxicity and encouraging response rate in heavily pretreated patients with FGFR-aberrant advanced solid malignancies.
